Severe Pneumonia Diagnostic in Pediatric Population by Lung Ultrasonography and Procalcitonin

Pneumonia Childhood Clinical Trial

— PROLUSP  

Official title:

Analysis of a Diagnostic Algorithm of Severe Pneumonia in Pediatric Critical Patients by Pulmonary Ultrasound and Procalcitonin as a Plan to Improve the Quality of Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04217980
• Other study ID #: FSJD-NEUMO-2017
• Status: Completed
• Phase: N/A
• Start date: September 21, 2017
• Est. completion date: December 3, 2019

Study information

• Verified date: January 2020
• Source: Fundació Sant Joan de Déu
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lung ultrasound (LUS) in combination with a biomarker has not yet been studied. The investigators propose a clinical trial where the primary aims are: 1. To assess whether an algorithm with LUS and procalcitonin (PCT) may be useful for diagnosing bacterial pneumonia; 2. To analyse the sensitivity and specificity of LUS vs chest radiograph (CXR).

Description:

Objectives: The general objective is to analyze whether a new algorithm approach of severe pneumonia in pediatric intensive unit (PICU) improves the quality of care. Objectives: 1- To analyze the sensitivity and specificity of lung ultrasound (LUS) compared respect to the chest radiography (CXR) in severe pneumonia and if LUS discriminates between bacterial and viral one. 2- If there is a lower CXR indication. 3- If is possible to reduce the dose of irradiation and costs associated with CXR. 4- To analyze the interobserver agreement of the LUS. 5- determine whether a diagnosis of pneumonia algorithm using LUS and procalcitonin may be useful in directing the indication of antibiotic therapy and / or the duration thereof.

Methodology: clinical, prospective, controlled, randomized, blinded intervention and 3-year trial. Inclusion of children under 18 years, with severe pneumonia, who enter (PICU). Experimental Group 1: pediatrician researcher (PR) will conduct a LUS at admission time, as a first test of lung image; in Group 2, CXR is conduced as first image. Patients will be classified into 3 subgroups, in both branches: a) if PCT is <1 ng /L and LUS is not suggestive of bacterial pneumonia, no antibiotic will be prescribed; b) if LUS is suggestive of bacterial pneumonia, regardless of the PCT, it will be recommended to start antibiotic therapy; c) If the ultrasound is suggestive of bacterial pneumonia but PCT is> 1 ng / L, antibiotic therapy will be recommended to cover other causes of infection. The same attitude will be performed, but depending on the CXR instead of the LUS, in group 2. Clinical variables, complementary tests and evolution data will be collected. Statistics by SPPS® 20.0. Informed consent will be requested and the study will be conducted according to the Helsinki Declaration guidelines and Good Clinical Practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 202
• Est. completion date: December 3, 2019
• Est. primary completion date: September 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• children under 18

• severe pneumonia criteria

• admitted at PICU

• informed consent signed

Exclusion Criteria:

• previous respiratory disease (cystic fibrosis and/or immunosuppression)

• Nosocomial pneumonia development while in charge for community pneumonia.

• Researcher pediatrician has valuated the chest X ray before the PICU admission

• Included in other clinical trial

Related Conditions & MeSH terms

• Pneumonia
• Pneumonia Childhood

Intervention

Diagnostic Test:
• Lung ultrasonography (LUS) or Chest X ray (CXR)
pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.

Locations

Country	Name	City	State
Spain	Hospital Sant Joan de Deu	Barcelona
Spain	Fundació Sant Joan de Déu	Esplugues de Llobregat

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Sant Joan de Déu

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensibility and specificity of LUS and procalcitonin for pneumonia diagnosis	Sens and Spe for LUS group and for X-Ray group	through study completion, an average of 2 years
Secondary	antibiotic days of treatment	antibiotic duration for CXR group and antibiotic duration for LUS group	through study completion, an average of 2 years